BioLife SolutionsBLFS +4.25%72 PS Ratio is 14.12 as of Jun. 27, 2026, which is 14% above its 10-year median of 12.36. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 87.31% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioLife Solutions's share price is $28.64.
BioLife Solutions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.03. Hence, BioLife Solutions's PS Ratio for today is 14.12.
Warning Sign:
BioLife Solutions Inc stock PS Ratio (=14.12) is close to 1-year high of 15.25.
The historical rank and industry rank for BioLife Solutions's PS Ratio or its related term are showing as below:
BLFS'
s PS Ratio Range Over the Past 10 Years
Min: 2.36 Med: 12.36 Max: 27.86
Current: 14.12
During the past 13 years, BioLife Solutions's highest PS Ratio was 27.86. The lowest was 2.36. And the median was 12.36.
BLFS's PS Ratio is ranked worse than 87.31% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs BLFS: 14.12
BioLife Solutions Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioLife Solutions was 21.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.10% per year.
During the past 13 years, BioLife Solutions's highest 3-Year average Revenue per Share Growth Rate was 416.20% per year. The lowest was -49.50% per year. And the median was 4.15% per year.
Back to Basics: PS Ratio
BioLife Solutions (NAS:BLFS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
BioLife Solutions PS Ratio Related Terms
BioLife Solutions PS Ratio Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BioLife Solutions's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's PS Ratio distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BioLife Solutions's Share Price of today is $28.64. BioLife Solutions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BioLife Solutions (BLFS) has a PS Ratio of 14.12 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioLife Solutions and its competitors. This is 14% above median its historical median of 12.36. Over the past decade, BioLife Solutions' PS Ratio has ranged from 2.36 to 27.86. According to the industry distribution chart, BioLife Solutions ranks #702 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 87.3%.
Is BioLife Solutions' PS Ratio too high?
BioLife Solutions' current PS Ratio of 14.12 is 14% above median its 10-year median of 12.36. Over the past 10 years, this metric has ranged from a low of 2.36 to a high of 27.86. The Medical Devices & Instruments industry median PS Ratio is 2.86. BioLife Solutions' value of 14.12 is 393.7% above this industry median. Based on the distribution chart, BioLife Solutions ranks #702 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' PS Ratio compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #702 out of 804 companies for PS Ratio. This places BioLife Solutions in the lower half of its industry. The industry median PS Ratio is 2.86. BioLife Solutions' value of 14.12 is 393.7% above this benchmark. Historically, BioLife Solutions' own PS Ratio has ranged from 2.36 to 27.86 over the past decade. While the company's 10-year median is 12.36 vs. the industry median of 2.86, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current PS Ratio of 14.12 is 393.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current PS Ratio is 14.12, which is 14% above median its own 10-year median of 12.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current PS Ratio is 14.12, which is 14% above median its 10-year median of 12.36 and 393.7% above the Medical Devices & Instruments industry median of 2.86. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current PS Ratio is 14.12 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
PS Ratio: 14.12 (14% above median its 10-year median of 12.36)
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
Industry Position: 393.7% above the Medical Devices & Instruments median (#702 of 804)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
